🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We welcome Diana, Rima and Helena! Diana David joins us as Executive Administrator to BigHat’s Corporate Dev & Ops team. Diana will support BigHat’s Leadership, Business Development, and Recruiting related administrative activities. After over two years of incredible work with

We’re thrilled to announce that Charbel Eid, VP of Platform at BigHat Biosciences, will be giving an invited talk at the upcoming @LRIG_ORG event! Charbel will be sharing insights into how BigHat is revolutionizing the development of next-generation antibody therapeutics through

We’re excited to share that Liz Schwarzbach, CBO of BigHat Biosciences, will be participating in a panel at Tough Tech Week 2024, titled Partnering for Speed & Progress in Human Health. In this discussion, Liz will draw on her experience to highlight how partnerships are

We welcome Taylor, Richard and Hector! Richard Gavan joins us as a Senior Software Engineer I, Lab Systems. Richard will play a key role in developing innovative software solutions for our Lab Systems team, collaborating across science and engineering to accelerate the design

Noelle Huskey, Principal Scientist, Translational Research at BigHat, will give her invited talk, “Functional and in vivo validation of next generation antibodies designed with a machine learning-driven synthetic biology platform” at the 16th annual Protein and Antibody

Today, we’re thrilled to announce that BigHat is developing a best-in-class ADC that combines our cutting-edge ML-guided antibody design platform with Synaffix B.V. (“Synaffix”), a Lonza company’s (SWX:LONN) site-specific linker-payload technology. With these next-gen

BigHat Biosciences is featured in STAT today’s “Who to Know: 7 companies to watch in AI protein design.” Read more about our work and how we’re advancing the field of next-generation biologics: statnews.com/2024/11/05/who…

We welcome Sebastian Ober, Fah Sathirapongsasuti and Nicholas Young. Sebastian joins BigHat’s Machine Learning team as Senior Machine Learning Scientist I. Sebastian will focus on improving BigHat’s integration of multimodal experimental data in Bayesian Optimization for

Hunter Elliott, BigHat’s Sr. Director of Machine Learning, as well as Alan Amin, from the Andrew Gordon Wilson lab at New York University, will be presenting a paper titled, “Bayesian Optimization of Antibodies Informed by a Generative Model of Evolving Sequences” at the NeurIPS Conference

BigHat’s VP of Discovery Medicine, Ryan Henrici, will be giving his invited talk "Machine Learning-guided Design of Logic Gated and Avidity-driven T Cell Engagers for Solid Malignancies” at the Antibody Engineering Conference on December 17th at 11 AM PST in San Diego. The talk will

This holiday we’re thankful for the expertise and hard work of our talented employees, advisors, partners, board of directors and investors. Please know we appreciate each and every one of your contributions. Thank you for being a BigHatter! BigHat Biosciences will be completely

BigHat is excited to kick off 2025 with a productive J.P. Morgan Healthcare Conference 2025! On Tuesday, January 14, 2025 our CEO, Mark DePristo, will speak on the Next in Tech Bio | Computational Strategies for Drug Discovery panel (⏰ 7:00PM @ 📍 Benchling) and CBO, Liz

Hunter Elliott (Sr. Director, Machine Learning) will give his invited talk “Generative and Predictive Machine Learning for Iterative Multi-Objective Therapeutic Antibody Optimization” at the Biologic Summit 2025 in San Diego on January 15, 2025. In this talk, Hunter explores how

BigHat’s machine learning team is excited to share its latest paper, in collaboration with the Gordon Wilson Lab at New York University, “Bayesian Optimization of Antibodies Informed by a Generative Model of Evolving Sequences,” which was accepted for publication at the prestigious

We are excited to share an important leadership update at BigHat Biosciences. Peyton Greenside has stepped into the role of CEO, bringing deep scientific expertise, strategic vision, and a strong commitment to our mission to develop better biologics through ML-guided design. We

We’re thrilled to share that Ryan Henrici, our VP of Discovery Medicine, has been selected as a recipient of Penn State's 2025 Alumni Achievement Award! This prestigious honor celebrates Ryan’s exceptional contributions to science and medicine—from his early academic

We welcome Michelle Gaus, Brendan Mullaney, and Glori Marie Roman! Glori joins BigHat’s as Scientist I, Molecular Biology. Glori Roman, PhD, is a chemical biologist with specialized expertise in antibody engineering and protein characterization. She obtained her BS in Chemistry